Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Hauser

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
Novartis Foundation Symposium|December 29, 2000
Transplantation of human fetal striatal tissue in Huntington's disease: rationale for clinical studiesT B Freeman, R A Hauser, A E Willing, et al.
Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration|June 1, 1996
Will fetal striatal transplants correct the akinetic end-stage of Huntington's disease?C V Borlongan, S Polgar, T B Freeman, et al.
Anatomical Record (Hoboken, N.J. : 2007)|August 30, 2025
A novel cartilage type in the sclera of Chelonia mydas: First reportA L M Souza, H Jerdy, L M Conti, et al.
Parkinsonism & Related Disorders|December 29, 2024
Duration of "Good On" time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT®)R A Hauser, H H Fernandez, J Jimenez-Shahed, et al.
Brain Research. Brain Research Protocols|August 1, 1997
Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3-nitropropionic acid modelC V Borlongan, T K Koutouzis, T B Freeman, et al.
Parkinsonism & Related Disorders|February 10, 2012
Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trialO Rascol, J Bronzova, R A Hauser, et al.
European Neurology|May 2, 2009
Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's diseaseR A Hauser, J Bronzova, C Sampaio, et al.
Archives of Neurology|February 20, 1999
Long-term evaluation of bilateral fetal nigral transplantation in Parkinson diseaseR A Hauser, T B Freeman, B J Snow, et al.
Neurology|April 28, 2004
Ropinirole for restless legs syndrome: a placebo-controlled crossover trialC H Adler, R A Hauser, K Sethi, et al.
Annals of Neurology|November 1, 1995
The effect of deprenyl and levodopa on the progression of Parkinson's diseaseC W Olanow, R A Hauser, L Gauger, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
Novartis Foundation Symposium|December 29, 2000
Transplantation of human fetal striatal tissue in Huntington's disease: rationale for clinical studiesT B Freeman, R A Hauser, A E Willing, et al.
Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration|June 1, 1996
Will fetal striatal transplants correct the akinetic end-stage of Huntington's disease?C V Borlongan, S Polgar, T B Freeman, et al.
Anatomical Record (Hoboken, N.J. : 2007)|August 30, 2025
A novel cartilage type in the sclera of Chelonia mydas: First reportA L M Souza, H Jerdy, L M Conti, et al.
Parkinsonism & Related Disorders|December 29, 2024
Duration of "Good On" time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT®)R A Hauser, H H Fernandez, J Jimenez-Shahed, et al.
Brain Research. Brain Research Protocols|August 1, 1997
Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3-nitropropionic acid modelC V Borlongan, T K Koutouzis, T B Freeman, et al.
Parkinsonism & Related Disorders|February 10, 2012
Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trialO Rascol, J Bronzova, R A Hauser, et al.
European Neurology|May 2, 2009
Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's diseaseR A Hauser, J Bronzova, C Sampaio, et al.
Archives of Neurology|February 20, 1999
Long-term evaluation of bilateral fetal nigral transplantation in Parkinson diseaseR A Hauser, T B Freeman, B J Snow, et al.
Neurology|April 28, 2004
Ropinirole for restless legs syndrome: a placebo-controlled crossover trialC H Adler, R A Hauser, K Sethi, et al.
Annals of Neurology|November 1, 1995
The effect of deprenyl and levodopa on the progression of Parkinson's diseaseC W Olanow, R A Hauser, L Gauger, et al.
Pageof 10